Want to join the conversation?
$BMY said its sales for Eliquis were $602MM in 4Q15, which more than doubled from 4Q14. Eliquis is the number one NOAC (novel anticoagulant) in new-to-brand patient share in cardiology across 12 markets around the world. The company continues to see strong demand trends from key markets such as the US, Germany and Japan.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.